Voyager Therapeutics names new CEO
This article was originally published in Scrip
Executive Summary
Interim president of R&D at Voyager Therapeutics, Dr Steven Paul, has been promoted to chief executive officer of the company. Dr Paul has been interim president since the company's launch in February 2014. Dr Paul is also a partner at venture capital firm Third Rock Ventures. He succeeds interim CEO Mark Levin, also a partner at Third Rock, who will become chair of Voyager's board of directors.
You may also be interested in...
Finding Value Left On The Shelf: Karuna Case Study
PureTech’s gamble to take an older Eli Lilly drug off the shelf to redevelop in a new indication paid off. The company aims to replicate this 'Karuna model' in the near future.
Podcast: NodThera On The Role Of The Brain In Driving Chronic Disease
Alan Watt, CEO of NodThera, a clinical-stage biotech developing brain-penetrant NLRP3 inflammasome inhibitors to treat chronic inflammatory diseases, talks to In Vivo about the company’s pipeline and recent data publication in the field of obesity.
Deals Of The Year 2023 Winners Revealed
For In Vivo's 16th annual Deals of the Year contest, we selected 12 nominees in three categories – Top Alliance, Top Financing and Top M&A. The polls are closed, and it is time to reveal the winners.